Introduction
============

Immunosuppressive drugs are used to improve the survival of a patient after organ transplantation by minimizing the reaction of the rejection of vascularized transplanted organs.[@b1-dddt-10-2899],[@b2-dddt-10-2899] The acute or chronic rejection of transplanted organs is a very complex process determined by several immunological and nonimmunological factors.[@b3-dddt-10-2899] Moreover, the choice of an appropriate immunosuppressive treatment protocol is of great importance.[@b4-dddt-10-2899]--[@b6-dddt-10-2899] Consideration should be given to protocols with low levels of adverse effects, so that approaches would largely translate into the quality of life of patients.

Many substances with immunosuppressive properties can be used together in different combinations on account of their multidirectional effects.[@b2-dddt-10-2899] For this reason, in clinical practice, immunosuppressive therapy in humans is based on multidrug regimens.[@b7-dddt-10-2899],[@b8-dddt-10-2899] However, the bulk of the published studies focus on the impact of individual drugs on organs and tissues, despite the fact that these drugs may affect each other's metabolism.[@b1-dddt-10-2899],[@b9-dddt-10-2899]--[@b11-dddt-10-2899]

Various systemic side effects are known to be caused by immunosuppressive drugs.[@b1-dddt-10-2899],[@b2-dddt-10-2899],[@b12-dddt-10-2899] As a result of the use of such drugs, a considerable decrease in the number of rejected transplants is seen, but this is often proportional to the increased incidence of infections and malignancies. Moreover, studies have shown that renal transplant recipients are at risk of the early occurrence of prostate cancer.[@b2-dddt-10-2899],[@b13-dddt-10-2899],[@b14-dddt-10-2899]

Proliferation processes are an important factor in maintaining normal graft function. Analogously, the appropriate structure of the glandular epithelium and the stroma of the prostate, as well as its function, depend on these processes.[@b15-dddt-10-2899] An important proliferation marker is proliferating cell nuclear antigen (PCNA). On the basis of expression studies of PCNA, this protein was determined to be a potential prognostic indicator that contributes to the development of predictive models for cancers and hyperplastic changes.[@b16-dddt-10-2899]--[@b19-dddt-10-2899]

Another factor that could be used to evaluate tissues in renal transplant recipients is the expression of intermediate filaments (IFs). Cytokeratin and desmin filaments play an important role in tissue regeneration and in proliferation processes.[@b20-dddt-10-2899]--[@b23-dddt-10-2899] It has been shown that cytokeratins participate in the resistance of cells against apoptosis, which plays a key role during the response to inflammation.[@b24-dddt-10-2899],[@b25-dddt-10-2899] Research shows that desmin is a marker of late-stage differentiation of smooth muscles, and the changes in its expression are an important prognostic factor for recurrences of prostate cancer.[@b26-dddt-10-2899] The expression patterns of IFs can serve as valuable phenotypic markers in both normal and malignant tissues. Moreover, the knowledge concerning the differentiated expression of IFs (especially cytokeratins) found a practical application in the pathomorphological diagnostics of the prostate.[@b26-dddt-10-2899]--[@b28-dddt-10-2899] Expression disorders of cytoskeleton proteins caused by immunosuppressive drugs may contribute to the occurrence of pathological changes in transplanted organs and tissues. Studies addressing this problem may shed some light on the changes caused by these drugs on the cellular level.

One sign of good health among experimental animals is body weight gain.[@b29-dddt-10-2899],[@b30-dddt-10-2899] The measurement of body weight is a simple but very effective way to assess the impact of treatment on important aspects such as appetite. It is worth mentioning that determination of body mass is important in the experimental model, which is proposed in this article, because immunosuppressive drugs have a narrow therapeutic window. Therefore, applied doses are calculated per unit of body weight to avoid the toxic effects of individual drugs associated with high doses.

There are many studies on the effects of immunosuppressants on the male reproductive system, especially on the testes,[@b31-dddt-10-2899]--[@b34-dddt-10-2899] but very few articles have dealt with the prostate.[@b35-dddt-10-2899]--[@b37-dddt-10-2899] Due to the absence of such information in the literature and given the increased risk of complications in transplant recipients, we have undertaken this research to determine the influence of different combinations of immunosuppressive drugs used in clinical practice on the morphology, ultrastructure, and expression of PCNA and cytoskeleton proteins in the rat dorsolateral prostate. It is worth mentioning that the results presented in this article are the continuation of our earlier studies.[@b37-dddt-10-2899]

Materials and methods
=====================

Animals
-------

The studies were conducted on 48 sexually mature 14-week-old male Wistar rats. The animals were obtained from a licensed breeding facility from the Institute of Occupational Medicine in Łódź, Poland. Prior to testing, all animals survived the 2-week adaptation period. Before starting the experiment, all animals were weighed, showing a mean weight of 305 g. The animals were housed in cages (six rats per cage) with a 12-hour light/12-hour dark cycle and divided into eight groups: a control group (I) and seven experimental groups (II--VIII). The rats in group I received a placebo. For the period of 6 months, the animals in the experimental groups were administered drugs in their pharmaceutical oral form (in bread pellets) including: rapamycin (Rapa), cyclosporin A (CsA), tacrolimus (Tac), mycophenolate mofetil (MMF), and prednisone (Pred), according to the standard three-drug regimens of immunosuppressive therapy used most frequently in clinical practice. The drug doses administered were based on the literature.[@b9-dddt-10-2899],[@b10-dddt-10-2899],[@b38-dddt-10-2899],[@b39-dddt-10-2899] The study scheme is presented in [Table 1](#t1-dddt-10-2899){ref-type="table"}.

Local ethical commission statement
----------------------------------

The protocol for this study was in accordance with National Research Council guidelines for the care and use of laboratory animals, and approved by the Local Commission of Ethics for the Care and Use of Laboratory Animals in Szczecin, Poland (permit number 26/2011). The animals had health certificates issued by a veterinarian. Each step of the study protocol was designed in such a way as to minimize the pain and distress of animals.

Collection of material for research
-----------------------------------

A total of 46 rats completed the study (two rats in group III died in the fourth month of the experiment). After 6 months, the animals were anesthetized with ketamine hydrochloride (50 mg/kg) and their body weights were measured. During the section, the dorsolateral prostates were obtained. We employed rat dorsolateral prostates in this research as they are homologous to the human prostate.[@b40-dddt-10-2899],[@b41-dddt-10-2899]

Morphological and ultrastructural studies
-----------------------------------------

Dorsal lobes of the rat prostates of the control and experimental groups were routinely fixed in 4% buffered paraformaldehyde and embedded in paraffin. The paraffin blocks were sliced into 3 μm sections. Next, the sections were stained using standard methods: hematoxylin and eosin, as well as periodic acid Schiff.[@b42-dddt-10-2899]

To evaluate the ultrastructure in the transmission electron microscope, the lobes of the rat prostates were cut into pieces of volume of **\~**1 mm^3^ and fixed in 2.5% glutaraldehyde solution (Sigma-Aldrich Co., St Louis, MO, USA) in 0.1 M cacodylate buffer (Sigma-Aldrich Co.) at pH 7.4 for 2 hours at 4°C. The material was then fixed in a 1% solution of osmium tetroxide (OsO4; Sigma-Aldrich Co.). The tissue was dehydrated in a series of ethanol and acetone (100%) and gradually supersaturated with Spurr epoxy resin (Polysciences, Inc., Warrington, PA, USA). Subsequently, the material was immersed in capsules filled with epoxy resin. The blocks were cut into ultrathin scraps of 70--80 nm thick. The collected sections were counterstained sequentially with 9% uranyl acetate (Sigma-Aldrich Co.) and 2.66% lead citrate (Sigma-Aldrich Co.).

The histological preparations were examined under a light microscope (BX41; Olympus Corporation, Tokyo, Japan), while the ultrastructure was evaluated with a transmission electron microscope JEM-100CX (JEOL, Tokyo, Japan). The study was blinded, and one experienced pathologist and two histologists independently evaluated the ultrastructure and the histological preparations stained with hematoxylin and eosin.

Immunohistochemistry
--------------------

For the immunohistochemical reactions, the following antibodies were used: monoclonal mouse antibody IgG against PCNA (clone PC10; Dako Denmark A/S, Glostrup, Denmark) diluted in the ratio of 1:200; monoclonal mouse antibody IgG against cytokeratin (clone MNF116; Dako Denmark A/S), which labels cytokeratins 5, 6, 8, 17, and probably 19, diluted in the ratio of 1:50; and monoclonal mouse antibody IgG against desmin (clone D33; Dako Denmark A/S) diluted in the ratio of 1:50.

The sections of the rat dorsolateral prostates were deparaffinized, hydrated, and boiled in target retrieval solution (Dako Denmark A/S) for 30 minutes at pH 6.0 (for desmin) and pH 9.0 (for PCNA and cytokeratin) to restore the antigens. The activity of endogenous peroxidase was blocked by using peroxidase blocking solution (Dako Denmark A/S) for 10 minutes. The sections were incubated at room temperature with mouse monoclonal primary antibodies in a humid chamber for 30 minutes. Primary antibodies were diluted in diluent (Dako Denmark A/S). Afterward, the sections were incubated with a complex containing secondary antibody conjugated with horseradish peroxidase (Dako REAL EnVision Detection System Peroxidase/diaminobenzidine+, rabbit/mouse; Dako Denmark A/S). After washing out the secondary antibody, diaminobenzidine (Dako Denmark A/S) was applied. As the final step, the slides were counterstained with Mayer's hematoxylin, dehydrated, and coverslipped. Each step of the procedure was preceded by washing the slides with phosphate-buffered saline. All reactions were performed simultaneously under the same conditions. The slides were examined under a light microscope (BX 41).

Quantitative computer image analysis of immunohistochemistry
------------------------------------------------------------

First, all the preparations were subjected to a scanning procedure (200× magnification, 0.25 μm resolution) with a ScanScope AT2 scanner (Leica Microsystems, Wetzlar, Germany). Next, the digital images of the slides thus obtained were analyzed on a computer screen using an ImageScope viewer (Version 11.2.0.780; Aperio Technologies, Inc., Vista, CA, USA). For the automatic computer analysis of the nuclear immunohistochemical PCNA reaction, nuclear v9 algorithm (Version 11.2.0.780; Aperio Technologies, Inc.) was used, whereas for cytoplasmic immunohistochemical reactions of cytokeratin and desmin, cytoplasmic v2 algorithm (Version 11.2.0.780; Aperio Technologies, Inc.) was employed. Other parameters were set in such a way as to achieve compliance with the visual evaluation of color intensity, taking into account the threshold for a positive result, namely a brown color of the nucleus or cytoplasm of the cells. Using each algorithm, the percentage of PCNA-positive cells was determined quantitatively and the number of desmin-and cytokeratin-positive cells with weak, moderate, and strong expression was calculated quantitatively. For cells with PCNA expression, the limit of the intensity threshold of the positive nuclei was 162--210 units; for the negative nuclei, this was \<162 units. For the cells with cytokeratin and desmin expression, the limit of the intensity threshold was 181--210 units for positive weak (+) cells, 151--180 units for positive moderate (++) cells, 120--150 units for positive strong (+++) cells, and \<120 units for negative cells. To obtain reliable and repeatable values, the total number of PCNA-, desmin-, and cytokeratin-positive cells was counted in 60 random fields (ten fields in six slides for each group) with an average area of 0.32 mm^2^ (for PCNA in the glandular part), 0.14 mm^2^ (for PCNA in the stroma), 0.24 mm^2^ (for cytokeratin), and 0.08 mm^2^ (for desmin).

Statistical analysis
--------------------

Statistical analysis was conducted using the Statistica 8.0 program for Windows (StatSoft, Krakow, Poland). For quantitative variables of PCNA-positive cells as well as for desmin- and cytokeratin-positive cells with weak, moderate, and strong expression in each group, the minimum and maximum values, arithmetic mean, and standard deviation were calculated. To assess the significance of the differences between the values obtained for each grade of the expression in each group, the Kruskal--Wallis test was performed. The variance analysis of Kruskal--Wallis was used due to the large deviation from the normal distribution. To assess the significance of the differences between the values obtained for PCNA-positive cells in the stroma and the glandular part in each group, a Mann--Whitney *U*-test was carried out. Differences were considered statistically significant when *P*-values were \<0.05.

Results
=======

An evaluation of the morphology and ultrastructure and the quantitative assessment of PCNA-positive cells were carried out in the glandular epithelium and stroma of rat dorsolateral prostates. Furthermore, a quantitative evaluation of desmin- and cytokeratin-positive cells with weak, moderate, and strong expression was conducted. The prostates of the animals from the experimental groups (II--VIII) and from the control group (I) were compared. Next, the groups in which the conversion of the treatment to Rapa took place were compared with the groups in which the treatment schemes did not include Rapa during the study.

Body mass
---------

Lower body masses were found in all the treated groups II--VIII ([Table 2](#t2-dddt-10-2899){ref-type="table"}). The rats in the control group had the highest body mass, whereas the animals in group II (*P*\<0.01), in which Rapa, Tac, and Pred were administered, had the lowest. Moreover, in group VI, in which the conversion of the treatment with CsA, MMF, and Pred on Rapa occurred, lower body mass was noted than in group V, in which CsA, MMF, and Pred were administered throughout the experiment. Moreover, in group VIII (in which the conversion of the treatment with Tac, MMF, and Pred on Rapa occurred), greater body mass was observed than in group VII, in which Tac, MMF, and Pred were administered throughout the experiment.

Morphology and ultrastructure
-----------------------------

In the glandular part of the rat dorsolateral prostate, the secretory and lead-out sections were lined with single-layer cubical or cylindrical epithelium. Periodic-acid-Schiff-positive eosinophilic secretion was observed in the lumen of the acini. In all the studied groups (II--VIII), changes were observed in the glandular epithelium, mainly in the apical and perinuclear part of the cell. Furthermore, two types of cells were observed -- with electron light and dark cytoplasm. Microvilli were seen on the cell surfaces.

### Group I: control

In the control group, acini in the rat dorsolateral prostate were lined with cubical or cylindrical epithelium ([Figure 1A](#f1-dddt-10-2899){ref-type="fig"}), in which no significant changes were observed. Proper cisterns of the rough endoplasmic reticulum in the perinuclear region ([Figure 2A](#f2-dddt-10-2899){ref-type="fig"}) and proper Golgi cisterns located in the apical part of the cells were observed. In many cells, different types of acini with transported secretion were present, which took on different forms (condensed, fluffy, and star shaped). In addition, in the perinuclear part of the cells, normal narrow parallel cisterns of rough endoplasmic reticulum were observed.

### Group II: Rapa, Tac, and Pred

In this group, the smallest changes were observed in the glandular epithelium, compared to other treatment groups. The glandular epithelium was characterized by small infoldings into the lumen of the acini. During the analysis of the ultrastructure, the epithelium showed the features of atrophy in a small area.

### Group III: Rapa, CsA, and Pred

In the acini, numerous infoldings of the glandular epithelium into the lumen of the acini were observed ([Figure 1B](#f1-dddt-10-2899){ref-type="fig"}). Moreover, in most of the cells, bloated cisterns were seen in the Golgi apparatus and in the rough endoplasmic reticulum ([Figure 2B](#f2-dddt-10-2899){ref-type="fig"}).

### Group IV: Rapa, MMF, and Pred

Similar to group III, multiple infoldings of the glandular epithelium into the lumen of the acini were observed in the rat dorsolateral prostates of group IV. In the lumen of some acini, inflammatory cells were also seen ([Figure 1C](#f1-dddt-10-2899){ref-type="fig"}). Bloated dictyosomes of Golgi apparatus and rough endoplasmic reticulum (RER) cisterns were also noticed. Moreover, some cells were characterized by disorder in the organization of organelles and by shrunken nucleus.

### Group V: CsA, MMF, and Pred

Highly atrophic epithelium was observed in many acini ([Figure 1D](#f1-dddt-10-2899){ref-type="fig"}). In several acini, hyperplasia of the glandular epithelium was also found. The presence of bloated Golgi apparatus cisterns in the apical part of the cells and of rough endoplasmic reticulum in the perinuclear region was noted. Condensed secretion was rarely observed in the secretory acini. On a large surface, the epithelium showed the features of atrophy with clear movement of the secretion apparatus ([Figure 2C](#f2-dddt-10-2899){ref-type="fig"}).

### Group VI: CsA, MMF, and Pred/Rapa

Many infoldings of the glandular epithelium into the lumen of acini were found. The epithelium did not show any characteristics of atrophy. In addition, numerous inflammatory cells in the lumen of the acini were observed, along with a disorder in the normal structure of the glandular epithelium ([Figure 1E](#f1-dddt-10-2899){ref-type="fig"}). These changes were accompanied by the foci of the hyperplasia of epithelial cells. Very large bloated cisterns of Golgi apparatus and rough endoplasmic reticulum were also noted. In this group, more severe morphological changes were observed than in group V.

### Group VII: Tac, MMF, and Pred

As in the case of group VI, numerous disorders of the normal structure of the epithelium, and focal hyperplasia of the glandular epithelium, were observed, though the changes were clearly smaller. Bloated RER was also seen in the perinuclear region of the cells. The Golgi apparatus was also characterized by bloated cisterns, and condensed secretion was present in the secretory acini.

### Group VIII: Tac, MMF, and Pred/Rapa

Focal hyperplasia of the glandular epithelium and infoldings of the epithelium into the lumen of the acini were observed. Moreover, in comparison to group VII, the changes identified in this group were clearly greater. In some areas, the epithelium showed features of atrophy. In addition, in the stroma, edema was observed within the walls of the acini ([Figure 1F](#f1-dddt-10-2899){ref-type="fig"}). As in the case of group VI, very large bloated cisterns of the secretion apparatus were found ([Figure 2D](#f2-dddt-10-2899){ref-type="fig"}).

Immunohistochemistry
--------------------

### PCNA

In the rat dorsolateral prostate, PCNA-positive cells were characterized by brown-stained nuclei ([Figure 3A and B](#f3-dddt-10-2899){ref-type="fig"}), in both the glandular epithelium and the stroma. The percentage of PCNA-positive cells in the control and experimental groups, in the glandular and stromal part, is presented in [Table S1](#SD1-dddt-10-2899){ref-type="supplementary-material"} and [Figure 4](#f4-dddt-10-2899){ref-type="fig"}.

The percentage values obtained for PCNA-positive cells in the glandular epithelium of the control group differed statistically significantly from those of groups III, IV, VI, and VIII (*P*\<0.001). The highest percentage of PCNA-positive cells in the glandular epithelium was noted in group IV, in which Rapa, MMF, and Pred were administered. The lowest percentage of PCNA-positive cells in the epithelium was observed in group VI, in which CsA, MMF, and Pred were administered in the first 3 months, but only Rapa in the next 3 months. The percentage values obtained for PCNA-positive cells in the stroma of the control group differed statistically significantly from those of groups III and VIII (*P*=0.034 and *P*\<0.001, respectively). The highest percentage of PCNA-positive cells in the stroma was found in group III (*P*=0.034), in which Rapa, CsA, and Pred were administered. The lowest percentage of PCNA-positive cells in the stroma was noted in group VIII (*P*\<0.001), in which Tac, MMF, and Pred were administered during the first 3 months and only Rapa in the next 3 months. The percentages of PCNA-positive cells in the glandular epithelium of all groups, apart from group VI, in comparison to the values for the stroma in particular groups, demonstrated statistically significant differences (*P*\<0.001). The percentage values obtained in group VI (in which CsA, MMF, and Pred were administered during the first 3 months and Rapa alone in the remaining period) were significantly lower than in group V, in which throughout the experiment CsA, MMF, and Pred were administered. The situation was similar when groups VII and VIII were compared. In group VIII (in which Tac, MMF, and Pred were administered for the first 3 months and Rapa alone during the next 3 months), the percentage of PCNA-positive cells was significantly lower than in group VII, in which Tac, MMF, and Pred were administered throughout the experiment.

### Cytokeratin

Cytokeratin-positive cells were found in the glandular epithelium and vascular endothelium of the stroma of the rat prostate. These cells were characterized by brown-stained cytoplasm ([Figure 3C and D](#f3-dddt-10-2899){ref-type="fig"}). The percentages of cytokeratin-positive cells with weak, moderate, and strong expression in individual groups (I--VIII) are presented in [Table S2](#SD2-dddt-10-2899){ref-type="supplementary-material"} and [Figure 5](#f5-dddt-10-2899){ref-type="fig"}. The percentage of cytokeratin-positive cells with weak, moderate, and strong expression in group I differed statistically from all the other groups: II, III, IV, V, VI, VII, and VIII (*P*=0.001 and *P*\<0.001, respectively). The highest percentage of cytokeratin-positive cells with weak expression was found in the control group (I), as well as in group II (*P*=0.001 vs control), in which Rapa, Tac, and Pred were administered. The lowest percentage of cytokeratin-positive cells with weak expression was found in group VII (*P*\<0.001 vs control), in which Tac, MMF, and Pred were administered. The highest percentage of cytokeratin-positive cells with moderate expression was found in group IV (*P*\<0.001 vs control), in which Rapa, MMF, and Pred were administered, and in group V (*P*\<0.001 vs control), in which CsA, MMF, and Pred were administered. The lowest percentage of cytokeratin-positive cells with moderate expression was found in the control group, as well as in group VIII (*P*\<0.001 vs control), in which Tac, MMF, and Pred were administered in the first 3 months and Rapa alone in the following 3 months. The highest percentage of cytokeratin-positive cells with strong expression was found in group VII (*P*\<0.001 vs control), in which Tac, MMF, and Pred were administered. The lowest percentage of cytokeratin-positive cells with strong expression was found in the control group, as well as in group II (*P*\<0.001 vs control), in which Rapa, Tac, and Pred were administered. In group VI (in which CsA, MMF, and Pred were administered in the first 3 months and Rapa along during the remaining period), the percentage of the cells showing moderate and strong expression of cytokeratin was lower (statistically insignificant) than in group V (in which CsA, MMF, and Pred were administered during the whole duration of the experiment). The comparison of groups VII and VIII gave similar outcomes.

### Desmin

Desmin-positive cells were localized in the stroma. The expression of desmin was observed in the smooth myocytes around the acini and in the smooth myocytes of the vascular walls; they were characterized by brown-stained cytoplasm ([Figure 3E and F](#f3-dddt-10-2899){ref-type="fig"}). The percentage of desmin-positive cells with weak, moderate, and strong expression in each of the groups (I--VIII) is presented in [Table S3](#SD3-dddt-10-2899){ref-type="supplementary-material"} and [Figure 6](#f6-dddt-10-2899){ref-type="fig"}.

The percentage of desmin-positive cells with weak expression of group I differed statistically significantly from that of groups II, V, VII, and VIII (*P*\<0.001). The highest percentage of desmin-positive cells with weak expression was found in group IV (statistically insignificant vs control), in which Rapa, MMF, and Pred were administered, and in group VI (statistically insignificant vs control), in which CsA, MMF, and Pred were administered in the first 3 months and Rapa alone in the following 3 months. The lowest percentage of desmin-positive cells with weak expression was found in group II (*P*\<0.001 vs control), in which Rapa, Tac, and Pred were administered. The percentage of desmin-positive cells with moderate expression for group I differed statistically significantly from that for groups III, IV, V, VII, and VIII (*P*\<0.001 and *P*=0.025, respectively). The highest percentage of desmin-positive cells with moderate expression was found in group VII (*P*\<0.001 vs control), in which Tac, MMF, and Pred were administered. The lowest percentage of desmin-positive cells with moderate expression was found in group IV (*P*\<0.001 vs control), in which Rapa, MMF, and Pred were administered. The percentage of desmin-positive cells with strong expression for group I differed statistically significantly from that for groups II, IV, V, VII, and VIII (*P*\<0.001 and *P*=0.002, respectively). The highest percentage of desmin-positive cells with strong expression was found in group II (*P*\<0.001 vs control), in which Rapa, Tac, and Pred were administered. The lowest percentage of desmin-positive cells with strong expression was found in group IV (*P*=0.002 vs control), in which Rapa, MMF, and Pred were administered. In group VI (in which CsA, MMF, and Pred were administered in the first 3 months and Rapa alone during the remaining period) the percentage of the cells showing moderate and strong expression of desmin was significantly lower than in group V (in which CsA, MMF, and Pred were administered throughout the experiment). Comparison of groups VII and VIII gave similar results. In group VIII (in which Tac, MMF, and Pred were administered in the first 3 months and Rapa alone during the next 3 months), the percentage of the cells showing moderate and strong desmin expression was significantly lower in comparison to group VII (in which Tac, MMF, and Pred were administered during the whole duration of the experiment).

Discussion
==========

In the available literature, there are few publications on the effects of different combinations of immunosuppressive drugs on the prostate. Only our earlier studies relate to the effects of various combinations of immunosuppressants on the morphology and the expression of PCNA and cytokeratin in the prostate.[@b37-dddt-10-2899],[@b43-dddt-10-2899] So far, no research has been found concerning the impact of the standard three-drug combinations of immunosuppressive drugs on the ultrastructure and the expression of desmin in the prostate. Moreover, a quantitative evaluation, with the division of the prostate into glandular and stromal parts, was performed. Our study can thus be regarded as innovative.

In the experiment conducted, it was attempted to develop a model of the action of the various immunosuppressive drugs that might be comparable to long-term immunosuppressive therapy in humans following organ transplantation. The experiment was conducted for 6 months owing to the fact that the rat's average life span varies from 2 years to 3 years, which refects \~12--15 years of a human life.[@b44-dddt-10-2899],[@b45-dddt-10-2899] As a result, the presented findings relate to the long-term effects of the particular combinations of immunosuppressive drugs. To compare, in many studies on the effects of immunosuppressive drugs on various organs, the time of the drug administration was relatively short.[@b10-dddt-10-2899],[@b32-dddt-10-2899],[@b35-dddt-10-2899],[@b46-dddt-10-2899] The fact that a physiological enteral route of the drug administration was chosen, rather than an intraperitoneal or intravenous route, as in some research on animal models, speaks to the advantage of the presented experimental model.[@b47-dddt-10-2899]--[@b49-dddt-10-2899]

In this experiment, a loss of body weight was observed in all the experimental rats. The highest (statistically significant) decrease in body mass was found in the animals in group II, in which Rapa, Tac, and Pred were administered. Other researchers have also observed a weight loss in both animals and humans undergoing immunosuppressive therapy.[@b31-dddt-10-2899],[@b35-dddt-10-2899],[@b47-dddt-10-2899],[@b50-dddt-10-2899]--[@b52-dddt-10-2899] The effect of particular immunosuppressive drugs on the body mass was also examined. Rovira et al[@b52-dddt-10-2899] observed that rats receiving CsA had higher body weight than animals on the CsA-free treatment scheme. In our experimental model, the positive effect exerted by CsA in CsA-based schemes on the weight of the rats was confirmed, while a considerable body weight loss was also found in rats treated with Rapa. Moreover, a decrease in the body weight was also found in the case of the conversion treatment from CsA-based regimens to Rapa. Other authors have also confirmed these observations.[@b50-dddt-10-2899] The weight loss caused by the administration of various combinations of immunosuppressive drugs may be related to their influence on cell growth processes and metabolism.

Both morphology and ultrastructure studies have shown that, in rat dorsolateral prostates in the group in which CsA, MMF, and Pred were administered, the epithelium was markedly atrophic. In our earlier studies conducted on the rat ventral prostate, a highly atrophied epithelium was observed in the group in which Rapa, CsA, and Pred were administered.[@b37-dddt-10-2899] This can be explained by the fact that the ventral lobe differs structurally and functionally from the dorsolateral unit.[@b41-dddt-10-2899] Unfortunately, other researchers have focused on identifying the impact of individual immunosuppressive drugs on the prostate.[@b35-dddt-10-2899],[@b36-dddt-10-2899] In our study, in all the groups, in which the atrophic epithelium was observed, calcineurin inhibitors (CsA or Tac) were administered. Some authors have observed that CsA causes a significant reduction in the absolute volume of all prostate components, including the epithelium in the ventral lobe of the rat prostate.[@b35-dddt-10-2899],[@b36-dddt-10-2899] These authors observed that, as a result of the administration of CsA, the glandular epithelial cells were clearly lower. Moreover, the ultrastructural analysis confirmed the epithelial atrophy. The morphological changes observed in groups with the conversion of the treatment to Rapa were more severe than in groups in which animals did not receive Rapa. Literature data confirm that, in rats, the conversion of the treatment from CsA to Rapa ultimately leads to larger structural damages and testicle dysfunctions than does the continuation of treatment with CsA.[@b50-dddt-10-2899]

In the glandular epithelium and stroma of the rat dorsolateral prostate, the lowest percentage of PCNA-positive cells was observed in groups with the conversion of the treatment to monotherapy with Rapa. Interestingly, these values were lower than in groups in which animals did not receive Rapa at all during the experiment. In our earlier studies on rat ventral prostates, the results had a similar distribution.[@b37-dddt-10-2899] Our results show that Rapa has antiproliferative activity. Other researchers have confirmed that Rapa exerts antiproliferative effects.[@b38-dddt-10-2899],[@b46-dddt-10-2899] In groups III and IV, in which rats received Rapa in combination with other drugs throughout the experiment, there were no fewer PCNA-positive cells than in the groups in which animals did not receive Rapa. The results were analogous in our earlier studies. In this experimental model, Rapa in combination with other drugs had less influence on the proliferation of cells in the dorsolateral lobe of the rat prostate. Unfortunately, we could not find any studies on the impact of immunosuppressive drugs on the expression of PCNA in the prostate. However, studies carried out on other models confirm the results obtained. Zhuang et al[@b53-dddt-10-2899] showed that the prolonged supply of Rapa inhibits the proliferation of PC-3 cells of prostate cancer. Other researchers[@b54-dddt-10-2899] have confirmed the antiproliferative properties of Rapa, observing that Rapa inhibits the proliferation of human keratinocyte stem cells by blocking the cell progression cycle in the G1 phase.

Cytokeratins constitute the most durable part of the cell cytoskeleton; for that reason, they are primarily responsible for protecting epithelial cells from mechanical tensions. They also play an important role in the regulation of cell growth.[@b20-dddt-10-2899],[@b21-dddt-10-2899] The expression of individual cytokeratins depends on the type of epithelium, the period of embryonic development, the level of cell differentiation, and the condition of the organism.[@b55-dddt-10-2899] Disturbances in the expression of cytokeratin may have a negative impact on processes in which regulation IFs are involved. In the dorsolateral lobe, in all the treatment groups (II--VIII), more cells exhibiting moderate and strong expression of cytokeratin were observed than in the control group. Unfortunately, we could not find any publications on the impact of even single immunosuppressant drugs on the organization of cytokeratin filaments in the prostate. The available literature indicates the negative impact of only certain immunosuppressive drugs on cytokeratins. Such studies have shown that CsA has a selectively toxic effect on cytokeratin filaments through a plurality of modifications in their structure. Research conducted on cell cultures subjected to 24 hours of exposure to CsA has shown that the fibers of the cytokeratin filaments are characterized by thickening and weakening adhesion to the cell membrane.[@b56-dddt-10-2899] Klawitter et al[@b57-dddt-10-2899] found that immunosuppressive drugs may increase the tissue concentration of selected cytoskeletal proteins. Other researchers confirm that CsA affects the organization of the cellular cytoskeleton.[@b58-dddt-10-2899] These reports may explain the increase in the expression of cytokeratin in the groups in which the treatment schemes contained CsA (III, V, VI). The results also show that Rapa causes a decrease in the expression of cytokeratin, in comparison to groups without the conversion to Rapa.

Research has shown that cytokeratin filaments are involved in the process of resistance against apoptosis.[@b24-dddt-10-2899],[@b25-dddt-10-2899] The resistance of epithelial cells to apoptosis is an important factor in the response to inflammation and is closely associated with the presence of cytokeratin filaments. As a result, it may be stated that mechanisms acting against inflammation could contribute to an increase in the expression of cytokeratins.

The smooth muscle cells (SMCs) of the prostate synthesize the regulatory and structural components of the extracellular matrix to create a microenvironment that regulates the growth and function of other cell types.[@b59-dddt-10-2899],[@b60-dddt-10-2899] Desmin is an integral part of the SMC and is necessary for maintaining both structural integrity and muscle function.[@b22-dddt-10-2899],[@b23-dddt-10-2899] It is also believed that desmin may be involved in the regulation processes of gene expression.[@b61-dddt-10-2899] Disorders in the expression of desmin may have a negative impact on processes in which this protein is involved.

The percentage of cells showing moderate and strong expression of desmin in groups with the conversion of treatment to monotherapy with Rapa was lower than in groups in which animals did not receive Rapa at all. Unfortunately, we could not find any publications on the impact of even single immunosuppressant drugs on the desmin in the prostate. Experiments on other experimental models can merely indirectly explain the decrease in the expression of desmin through the inhibition of muscle cell proliferation. Poon et al[@b62-dddt-10-2899] showed that Rapa inhibits the ability of vascular SMCs to migrate. Moreover, the inhibitory effect on the migration of SMC was maintained for up to 2 weeks after the administration of Rapa was halted. Li et al[@b22-dddt-10-2899] confirmed the antiproliferative effects of Rapa on SMCs.

Studies suggest that many patients who have undergone kidney transplantation continue to report sexual dysfunctions despite normal graft function.[@b63-dddt-10-2899],[@b64-dddt-10-2899] Many factors influence the proper function of the male reproductive systems in these individuals, including age, comorbid diseases, and the received immunosuppressive drugs as an integral part of therapy. It has been shown that, in patients who have received transplants, immunosuppressive drugs are the main cause of reduction in testosterone and of the occurrence of histopathological changes in the gonads.[@b31-dddt-10-2899],[@b50-dddt-10-2899],[@b65-dddt-10-2899] However, it is known that not only the testes but also other organs are responsible for fertility and reproductive capacity. Therefore, research into the influence of immunosuppressive drugs on other organs of the male reproductive system, including the prostate, seems to be justified.

Conclusion and perspectives
===========================

It can be stated that, in the case of rats whose treatment was switched to monotherapy with Rapa during the study treatment, a decreased percentage of proliferating cells of both the glandular epithelium and stroma was found. The presented results provide further evidence for and justify the use of inhibitors of the mammalian target of Rapa in the treatment of patients with cancers, including men suffering from prostate cancer following kidney transplantation.

Based on these results, it may be also stated that immunosuppressive drugs in combination with Rapa, Tac, and Pred caused the smallest morphological and ultrastructural changes in rat prostate cells. Another advantage of this combination is the percentage of proliferating cells, which was similar to that in the control group. If the prostate is considered in isolation from the other organs of the body, this treatment scheme would seem to be the most beneficial for patients who do not suffer from prostate diseases. However, it must be remembered that an immunosuppressive therapy must always be tailored individually to the patient and must take into account any comorbid diseases.

Conducted experiment has also shown abnormalities in the ultrastructure of the prostate cells of the rats. The numerous distended cisterns of the Golgi apparatus and of the rough endoplasmic reticulum may explain the irregularities in the synthesis and secretion processes. The observed changes indicate the adverse effects of the immunosuppressive drugs on processes occurring on the intracellular level.

It is difficult to clearly interpret the observed changes in the expression of cytokeratin and desmin in the rat dorsolateral prostate. The changes in the expression profiles of the cytoskeleton proteins in the experimental groups may be the result of the direct adverse effects of the immunosuppressive drugs on the structure and organization of the IF proteins. Moreover, a number of defense mechanisms against inflammation could be activated in the cells, which, in result, could contribute to an increase in the expression of cytokeratins. The increase in the expression of these proteins may also indicate an increase in cell resistance to the apoptosis process.

Hopefully, our results not only contribute to the deeper understanding of the processes occurring in the prostate in patients undergoing immunosuppressive therapy but will also help in the individual selection of the most favorable treatment regimens that best minimize the future risk of complications, especially in men planning fatherhood.

Supplementary materials
=======================

###### 

Percentage of PCNA-positive epithelial and stromal cells in the rat dorsolateral prostate in control (I) and experimental (II--VIII) groups

  Group   Given drugs           PCNA-positive cells in epithelium (%)   PCNA-positive cells in stroma (%)                                                                                                                            
  ------- --------------------- --------------------------------------- ----------------------------------- ---------------------------------------------------------------------------------------------------- ------------ ------ ----------------------------------------------------------------------------------------------------
  I       --                    12.7--30.4                              22.3                                22.3±4.1                                                                                             6.5--25.0    15.6   16.0±3.6
  II      Rapa, Tac, Pred       15.2--31.6                              22.4                                22.5±4.0                                                                                             10.0--25.4   16.9   16.6±3.8
  III     Rapa, CsA, Pred       17.7--36.7                              30.0                                29.3[\*](#tfn6-dddt-10-2899){ref-type="table-fn"}±4.6                                                12.5--28.4   18.0   18.6[\*](#tfn6-dddt-10-2899){ref-type="table-fn"}±3.9
  IV      Rapa, MMF, Pred       23.5--36.0                              30.8                                30.0[\*](#tfn6-dddt-10-2899){ref-type="table-fn"}±3.3                                                11.8--24.3   18.3   18.3±3.6
  V       CsA, MMF, Pred        17.2--31.0                              22.5                                22.9±3.3                                                                                             9.6--25.0    15.8   17.2±4.5
  VI      CsA, MMF, Pred/Rapa   10.1--31.3                              15.7                                16.0[a](#tfn7-dddt-10-2899){ref-type="table-fn"},[\*](#tfn6-dddt-10-2899){ref-type="table-fn"}±4.2   9.0--25.0    14.8   14.8[a](#tfn7-dddt-10-2899){ref-type="table-fn"}±3.6
  VII     Tac, MMF, Pred        16.1--34.8                              23.7                                24.3±4.8                                                                                             10.9--23.6   16.6   16.4±2.9
  VIII    Tac, MMF, Pred/Rapa   8.6--23.3                               15.8                                16.6[a](#tfn7-dddt-10-2899){ref-type="table-fn"},[\*](#tfn6-dddt-10-2899){ref-type="table-fn"}±3.2   3.8--17.4    12.1   11.1[a](#tfn7-dddt-10-2899){ref-type="table-fn"},[\*](#tfn6-dddt-10-2899){ref-type="table-fn"}±3.7

**Notes:**

*P*\<0.05 vs control.

Groups with the conversion of the treatment to Rapa, significantly different (*P*\<0.05) vs the groups without Rapa (VI vs V and VIII vs VII).

**Abbreviations:** CsA, cyclosporin A; Me, median; Min-max, minimum-maximum values; MMF, mycophenolate mofetil; Rapa, rapamycin; PCNA, proliferating cell nuclear antigen; Pred, prednisone; Tac, tacrolimus; $\overline{x}$ ± SD, mean ± standard deviation.

###### 

Percentage of cytokeratin-positive cells in the rat dorsolateral prostate in control (I) and experimental (II--VIII) groups

  Group   Given drugs           Cells with weak expression of cytokeratin (%)   Cells with moderate expression of cytokeratin (%)   Cells with strong expression of cytokeratin (%)                                                                                                                                                       
  ------- --------------------- ----------------------------------------------- --------------------------------------------------- ----------------------------------------------------------------------------------------------------- ------------ ------ ------------------------------------------------------- ------------ ------ -----------------------------------------------------------------------------------------------------
  I       --                    36.1--71.0                                      58.8                                                58.4±7.3                                                                                              1.0--30.7    13.2   14.4±8.5                                                0.1--7.7     0.6    1.6± 1.8
  II      Rapa, Tac, Pred       16.0--50.7                                      41.8                                                39.5[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±8.3                                                 16.6--53.9   37.9   36.2[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±9.7   6.5--38.0    14.4   16.0[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±7.0
  III     Rapa, CsA, Pred       19.4--49.7                                      30.7                                                32.2[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±7.5                                                 26.3--57.2   43.9   43.0[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±6.9   4.3--42.3    22.3   21.0[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±9.8
  IV      Rapa, MMF, Pred       10.0--39.2                                      23.9                                                24.7[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±7.3                                                 20.7--56.5   46.6   44.2[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±8.0   9.3--44.8    25.3   26.1[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±9.6
  V       CsA, MMF, Pred        10.4--45.6                                      28.9                                                28.2[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±7.6                                                 34.9--55.0   45.2   44.2[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±5.5   9.6--47.1    23.2   24.5[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±8.8
  VI      CsA, MMF, Pred/Rapa   18.3--54.4                                      31.2                                                30.5[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±8.3                                                 10.1--51.2   40.8   38.8[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±9.0   1.5--39.7    22.9   22.9[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±9.6
  VII     Tac, MMF, Pred        4.1--34.3                                       16.3                                                17.6[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±6.7                                                 21.8--50.1   38.1   37.3[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±7.4   21.2--61.8   43.7   44.0[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±9.6
  VIII    Tac, MMF, Pred/Rapa   11.2--45.3                                      28.7                                                27.8[a](#tfn10-dddt-10-2899){ref-type="table-fn"},[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±8.9   18.4--50.7   33.0   34.8[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±7.7   14.6--46.6   30.4   30.4[a](#tfn10-dddt-10-2899){ref-type="table-fn"},[\*](#tfn9-dddt-10-2899){ref-type="table-fn"}±9.8

**Notes:**

*P*\<0.05 vs control.

Groups with the conversion of the treatment to Rapa, significantly different (*P*\<0.05) vs the groups without Rapa (VI vs V and VIII vs VII).

**Abbreviations:** CsA, cyclosporin A; Me, median; Min-max, minimum-maximum values; MMF, mycophenolate mofetil; Pred, prednisone; Rapa, rapamycin; Tac, tacrolimus; $\overline{x}$ ± sD, mean ± standard deviation.

###### 

Percentage of desmin-positive cells in the rat dorsolateral prostate in control (I) and experimental (II--VIII) groups

  Group   Given drugs           Cells with weak expression of desmin (%)   Cells with moderate expression of desmin (%)   Cells with strong expression of desmin (%)                                                                                                                                                               
  ------- --------------------- ------------------------------------------ ---------------------------------------------- --------------------------------------------------------- ------------ ------ ------------------------------------------------------------------------------------------------------ ------------ ------ ---------------------------------------------------------
  I       --                    29.2--60.7                                 51.5                                           50.3±7.7                                                  17.5--48.3   31.3   31.1±6.7                                                                                               0.9--22.9    4.4    5.9±4.9
  II      Rapa, Tac, Pred       7.6--47.0                                  22.9                                           22.8[\*](#tfn12-dddt-10-2899){ref-type="table-fn"}±6.8    17.4--39.4   26.9   27.0±5.5                                                                                               16.8--69.0   44.2   45.7[\*](#tfn12-dddt-10-2899){ref-type="table-fn"}±10.3
  III     Rapa, CsA, Pred       32.4--69.9                                 47.8                                           48.9±9.1                                                  7.4--33.0    17.2   17.9[\*](#tfn12-dddt-10-2899){ref-type="table-fn"}±5.2                                                 0.2--10.1    1.9    2.4±2.0
  IV      Rapa, MMF, Pred       36.6--69.9                                 52.1                                           52.2±7.7                                                  1.2--23.0    11.3   11.9[\*](#tfn12-dddt-10-2899){ref-type="table-fn"}±4.5                                                 0.1--6.6     1.1    1.5[\*](#tfn12-dddt-10-2899){ref-type="table-fn"}± 1.4
  V       CsA, MMF, Pred        11.1--42.3                                 28.5                                           27.3[\*](#tfn12-dddt-10-2899){ref-type="table-fn"}±7.9    25.6--56.1   41.0   41.2[\*](#tfn12-dddt-10-2899){ref-type="table-fn"}±6.8                                                 11.6--43.8   27.7   27.8[\*](#tfn12-dddt-10-2899){ref-type="table-fn"}±7.8
  VI      CsA, MMF, Pred/Rapa   36.4--67.1                                 52.1                                           52.2[a](#tfn13-dddt-10-2899){ref-type="table-fn"}±6.4     13.8--43.2   33.3   32.9[a](#tfn13-dddt-10-2899){ref-type="table-fn"}±6.3                                                  0.6--18.7    6.7    7.2[a](#tfn13-dddt-10-2899){ref-type="table-fn"}±3.7
  VII     Tac, MMF, Pred        15.0--39.6                                 26.1                                           26.4[\*](#tfn12-dddt-10-2899){ref-type="table-fn"}±6.7    34.1--58.1   48.7   47.4[\*](#tfn12-dddt-10-2899){ref-type="table-fn"}±5.9                                                 9.2--36.2    22.7   23.3[\*](#tfn12-dddt-10-2899){ref-type="table-fn"}±7.0
  VIII    Tac, MMF, Pred/Rapa   14.7--55.1                                 30.5                                           32.6[\*](#tfn12-dddt-10-2899){ref-type="table-fn"}±11.8   20.4--58.0   36.7   38.8[a](#tfn13-dddt-10-2899){ref-type="table-fn"},[\*](#tfn12-dddt-10-2899){ref-type="table-fn"}±9.6   5.4--37.6    21.9   22.6[\*](#tfn12-dddt-10-2899){ref-type="table-fn"}±9.2

**Notes:**

*P*\<0.05 vs control.

Groups with the conversion of the treatment to Rapa, significantly different (*P*\<0.05) vs the groups without Rapa (VI vs V and VIII vs VII).

**Abbreviations:** CsA, cyclosporin A; Me, median; Min-max, minimum-maximum values; MMF, mycophenolate mofetil; Rapa, rapamycin; Pred, prednisone; Tac, tacrolimus; $\overline{x}$ ± SD, mean ± standard deviation.
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![Morphology of the rat dorsolateral prostate.\
**Notes:** (**A**) Epithelial cells (arrows) of the control group (I). (**B**) Numerous papillary infoldings of the glandular epithelium protruding into the acini lumen (arrows), hyperplastic epithelium, group III. (**C**) Inflammatory cells in the lumen of some acini (arrows), group IV. (**D**) Distinctly atrophic epithelium (arrows), group V. (**E**) Disorder of the normal structure of the epithelium (arrows), cells of different height, focal hyperplasia, group VI. (**F**) Edema (arrows) in the walls of acini in the stroma, group VIII. H&E staining, magnification ×600. I: control group; III, IV, V, VI and VIII: experimental groups.\
**Abbreviation:** H&E, hematoxylin and eosin.](dddt-10-2899Fig1){#f1-dddt-10-2899}

![Ultrastructure of the rat dorsolateral prostate.\
**Notes:** (**A**) Proper cisterns of the rough endoplasmic reticulum in the perinuclear region (arrow) of the control group (I), ×10,200. (**B**) Bloated cisterns of the rough endoplasmic reticulum (arrows). Group III, ×10,200. (**C**) Epithelium showing the features of atrophy with movement of the secretion apparatus from the supernuclear region to the side part of the cell (arrow), group V, ×6,600. (**D**) Bloated cisterns of the Golgi apparatus (arrow), group VIII, ×6,600. I: control group; III, V and VIII: experimental groups.](dddt-10-2899Fig2){#f2-dddt-10-2899}

![Immunolocalization and immunoexpression of PCNA (**A**, **B**), cytokeratin (**C**, **D**), and desmin (**E**, **F**) in the rat dorsolateral prostate.\
**Notes:** (**A**, **B**) PCNA-positive cells of the glandular epithelium (arrows). (**A**) Control group (I), (**B**) group III. (**C**, **D**) Cytokeratin-positive cells of the glandular epithelium (arrows). (**C**) Control group (I), (**D**) group VII. (**E**, **F**) Desmin-positive cells of the smooth myocytes around acini (arrows). (**E**) Control group (I), (**F**) group VII. Magnification ×600. I: control group; III and VII: experimental groups.\
**Abbreviation:** PCNA, proliferating cell nuclear antigen.](dddt-10-2899Fig3){#f3-dddt-10-2899}

![Percentage of PCNA-positive cells in epithelium and stroma in the rat dorsolateral prostate in control (I) and experimental groups (II--VIII).\
**Notes:** a, significantly different vs the controls in epithelial cells; b, groups with the conversion of the treatment to Rapa, significantly different vs the groups without Rapa in epithelial cells (VI vs V and VIII vs VII); c, significantly different vs controls in stromal cells; d, groups with the conversion of the treatment to Rapa, significantly different vs the groups without Rapa in stromal cells (VI vs V and VIII vs VII); e, PCNA-positive epithelial cells, significantly different vs PCNA-positive stromal cells.\
**Abbreviations:** CsA, cyclosporin A; MMF, mycophenolate mofetil; Rapa, rapamycin; PCNA, proliferating cell nuclear antigen; Pred, prednisone; Tac, tacrolimus.](dddt-10-2899Fig4){#f4-dddt-10-2899}

![Percentage of cytokeratin-positive cells in epithelium in the rat dorsolateral prostate in control (I) and experimental groups (II--VIII).\
**Notes:** a, significantly different vs the controls for the cells with weak expression; b, significantly different vs the controls for the cells with moderate expression; c, significantly different vs the controls for the cells with strong expression; d, groups with the conversion of the treatment to Rapa, significantly different vs the groups without Rapa (VI vs V and VIII vs VII) for the cells with weak expression; e, groups with the conversion of the treatment to Rapa, significantly different vs the groups without Rapa (VI vs V and VIII vs VII) for the cells with strong expression.\
**Abbreviations:** CsA, cyclosporin A; MMF, mycophenolate mofetil; Rapa, rapamycin; Pred, prednisone; Tac, tacrolimus.](dddt-10-2899Fig5){#f5-dddt-10-2899}

![Percentage of desmin-positive cells in epithelium in the rat dorsolateral prostate in control (I) and experimental groups (II--VIII).\
**Notes:** a, significantly different vs the controls for the cells with weak expression; b, significantly different vs the controls for the cells with moderate expression; c, significantly different vs the controls for the cells with strong expression; d, groups with the conversion of the treatment to Rapa, significantly different vs the groups without Rapa (VI vs V and VIII vs VII) for the cells with weak expression; e, groups with the conversion of the treatment to Rapa, significantly different vs the groups without Rapa (VI vs V and VIII vs VII) for the cells with moderate expression; f, groups with the conversion of the treatment to Rapa, significantly different vs the groups without Rapa (VI vs V and VIII vs VII) for the cells with strong expression.\
**Abbreviations:** CsA, cyclosporin A; MMF, mycophenolate mofetil; Rapa, rapamycin; Pred, prednisone; Tac, tacrolimus.](dddt-10-2899Fig6){#f6-dddt-10-2899}

###### 

Study scheme

  Group                                                                   Number of rats   Given drugs (pharmaceutical form)                  Dose (mg/kg of body weight/day)   Feeding time
  ----------------------------------------------------------------------- ---------------- -------------------------------------------------- --------------------------------- ----------------
  I                                                                       6                --                                                 --                                --
  II                                                                      6                Rapa (Rapamune; Pfizer, Inc., New York, NY, USA)   0.5                               6 months
  Tac (Prograf; Astellas Pharma Inc., Tokyo, Japan)                       4                                                                                                     
  Pred (Encorton; Polfa, Pabianice, Poland)                               4                                                                                                     
  III                                                                     6/4              Rapa (Rapamune)                                    0.5                               6 months
  CsA (Sandimmum-Neoral; Novartis International AG, Basel, Switzerland)   5                                                                                                     
  Pred (Encorton)                                                         4                                                                                                     
  IV                                                                      6                Rapa (Rapamune)                                    0.5                               6 months
  MMF (CellCept; Hoffman-La Roche Ltd., Basel, Switzerland)               20                                                                                                    
  Pred (Encorton)                                                         4                                                                                                     
  V                                                                       6                CsA (Sandimmum-Neoral)                             5                                 6 months
  MMF (CellCept)                                                          20                                                                                                    
  Pred (Encorton)                                                         4                                                                                                     
  VI                                                                      6                CsA (Sandimmum-Neoral)                             5                                 First 3 months
  MMF (CellCept)                                                          20                                                                                                    
  Pred (Encorton)                                                         4                                                                                                     
  Rapa (Rapamune)                                                         0.5              Last 3 months                                                                        
  VII                                                                     6                Tac (Prograf)                                      4                                 6 months
  MMF (CellCept)                                                          20                                                                                                    
  Pred (Encorton)                                                         4                                                                                                     
  VIII                                                                    6                Tac (Prograf)                                      4                                 First 3 months
  MMF (CellCept)                                                          20                                                                                                    
  Pred (Encorton)                                                         4                                                                                                     
  Rapa (Rapamune)                                                         0.5              Last 3 months                                                                        

**Notes:** Drugs were given to rats in accordance with the regimens applied in clinical practice. I, control group; II--VIII, experimental groups. 6/4: Two rats died in the fourth month of the experiment.

**Abbreviations:** CsA, cyclosporin A; MMF, mycophenolate mofetil; Pred, prednisone; Rapa, rapamycin; Tac, tacrolimus.

###### 

Body mass of rats

  Group   Given drugs           Body mass (g)                                                      
  ------- --------------------- ---------------------------------------------------------- ------- ----------
  I       --                    572.9±78.1                                                 574     474--700
  II      Rapa, Tac, Pred       403.0[\*](#tfn14-dddt-10-2899){ref-type="table-fn"}±54.3   417     331--480
  III     Rapa, CsA, Pred       467.0±54.9                                                 470     398--530
  IV      Rapa, MMF, Pred       435.7±58.3                                                 414     385--546
  V       CsA, MMF, Pred        544.2±50.2                                                 554     481--600
  VI      CsA, MMF, Pred/Rapa   428.8±53.9                                                 472.5   411--563
  VII     Tac, MMF, Pred        482.5±66.7                                                 482.5   405--580
  VIII    Tac, MMF, Pred/Rapa   502.8±38.5                                                 494.5   465--569

**Notes: I**, control group; II--VIII, experimental groups.

*P*\<0.05.

**Abbreviations:** CsA, cyclosporin A; Me, median; Min-max, minimum-maximum values; MMF, mycophenolate mofetil; Rapa, rapamycin; Pred, prednisone; Tac, tacrolimus; $\overline{x}$ ± SD, mean ± standard deviation.
